Levodropropizine - CAS 99291-25-5
Catalog number: 99291-25-5
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Histamine Receptor
Levodropropizine possess anti-allergic and inhibits histamine receptor, reduces cough by interfering with stimulus activation of peripheral endings of sensory nerves and by modulation of neuropeptides involved in the cough reflex.
Canonical SMILES:
1.Levodropropizine does not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment.
Bruschi C;Crotti P;Dacosto E;Fanfulla F;Daffonchio L;Novellini R Pulm Pharmacol Ther. 2003;16(4):231-6.
To evaluate whether the peripherally acting antitussive levodropropizine could affect the respiratory drive and the breathing pattern, we performed a double-blind, randomised, cross-over trial in 12 healthy volunteers and 12 patients with chronic respiratory impairment associated with chronic obstructive pulmonary disease. Levodropropizine 6% drops (at the recommended dose for adults) or placebo were administered orally t.i.d. for 10 consecutive administrations. Mouth occlusion pressure (P0.1), minute ventilation (V(e)), tidal volume (V(t)), respiratory rate (RR), mean inspiratory flow (V(t)/T(i)), end-tidal CO(2) (EtCO(2)), oxygen saturation (SaO(2)), forced expiratory volume in 1 s (FEV(1)), and the response to a hypercapnic stimulus were measured before and 1 h after the first and the last drug administration. Levodropropizine did not modify P0.1 in basal conditions and after a hypercapnic stimulus, either in healthy volunteers or in patients. In parallel, levodropropizine did not significantly affect V(t), RR, V(e), V(t)/T(i) and EtCO(2) in both the populations. Minor changes were induced by levodropropizine on SaO(2) in healthy volunteers, which despite a statistical difference, were too low to gain a clinical significance.
2.Currently available cough suppressants for chronic cough.
Chung KF Lung. 2008;186 Suppl 1:S82-7. Epub 2007 Oct 2.
Chronic cough is a common symptom but only a fraction of patients seek medical attention. Addressing the causes of chronic cough may lead to control of cough; however, this approach is not always successful since there is a certain degree of failure even when the cause(s) of cough are adequately treated; in idiopathic cough, there is no cause to treat. Persistent cough may be associated with deterioration of quality of life, and treatment with cough suppressants is indicated. Currently available cough suppressants include the centrally acting opioids such as morphine, codeine, and dextromethorphan. Peripherally acting antitussives include moguisteine and levodropropizine. Early studies report success in reducing cough in patients with chronic bronchitis or COPD; however, a carefully conducted study showed no effect of codeine on cough of COPD. Success with these cough suppressants can be achieved at high doses that are associated with side effects. Slow-release morphine has been reported to be useful in controlling intractable cough with good tolerance to constipation and drowsiness. There have been case reports of the success of centrally acting drugs such as amitryptiline, paroxetine, gabapentin, and carbamezepine in chronic cough.
3.[Evaluation of the treatment with levodropropizine of respiratory diseases in children].
Fiocchi A;Zuccotti GV;Vignati B;Pogliani L;Sala M;Riva E Pediatr Med Chir. 1989 Sep-Oct;11(5):519-22.
Sometimes, antitussives can be a valid adjuvant to respiratory tract infections treatment. Although not always needed, this therapeutic support can be extremely useful in selected cases, and when patient is resident and monitored. In this line, the efficacy of a new peripheral antitussive, levodropropizine (Dompé farmaceutici, Milan), has been evaluated in 70 children inpatients of the Pediatric Department at san Paolo Hospital - Milan University - from September 1987 to May 1988. Thirty one male and 29 female children, aged 4 years and 6 months +/- 3 years and 5 months, suffering from various respiratory tract diseases were included in the study. Underlying diseases were represented by 21 acute bronchitis, 20 asthmatic attacks, 18 bronchopneumonia, 11 tracheitis, 6 acute episodes of chronic bronchitis, 2 hypoglottis laryngitis, 1 pertussis, 1 spontaneous pneumothorax. All parents gave their oral informed consent. The basic treatments were antibiotics in 44 patients associated or not with beta 2 agonists (31), theophylline (15), corticosteroids via aerosol (9) or parenterally (3), immunomodulators (2). Treatment with levodropropizine in the oral drops formulation at 2 mg pro kg a day was continued for 5 days and withdrawn according to the clinical evolution.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Histamine Receptor Products

CAS 69014-14-8 Tiotidine

(CAS: 69014-14-8)

Tiotidine is a potent histamine H2 receptor antagonist with negligible activity against H1- and H3- receptors.

CAS 3614-69-5 Dimetindene maleate

Dimetindene maleate
(CAS: 3614-69-5)

Dimethindene is a histamine H1 antagonist of high potency used orally and locally as an antipruritic.

CAS 177708-09-7 Proxyfan oxalate

Proxyfan oxalate
(CAS: 177708-09-7)

Proxyfan oxalate is a high affinity histamine H3 receptor ligand (pKi = 8.62), acting as a protean agonist with activity ranges from full agonist to inverse ago...

CAS 85604-00-8 Zaltidine

(CAS: 85604-00-8)

Zaltidine is an effective but hepatotoxic H2-receptor antagonist. It has higher incidence of hepatic damage than with commonly used H2-receptor antagonists. It ...

CAS 77-38-3 Chlorphenoxamine

(CAS: 77-38-3)

Chlorphenoxamine is an analog of diphenhydramine. It has antimuscarinic and antihistaminic properties. It has been used as an antipruritic and antiparkinsonian ...

CAS 86-22-6 brompheniramine

(CAS: 86-22-6)

Brompheniramine an antihistamine drug.It belongs to the propylamine class. It can be used for the treatment of the symptoms of the common cold and allergic rhin...

CAS 108498-50-6 FRG8701

(CAS: 108498-50-6)

FRG-8701 is a novel Histamine H2 receptor antagonist (IC50= 0.25~ 0.43 μM). FRG-8701 has relatively long-lasting antisecretory ef fects in comparison with famot...

CAS 3343-39-3 2-Pyridylethylamine dihydrochloride

2-Pyridylethylamine dihydrochloride
(CAS: 3343-39-3)

2-Pyridylethylamine dihydrochloride is a histamine H1 receptor agonist that produces vasoconstriction.

CAS 5579-84-0 Betahistine dihydrochloride

Betahistine dihydrochloride
(CAS: 5579-84-0)

Betahistine is a histamine H3 receptors inhibitor with IC50 of 1.9 μM.

CAS 184576-87-2 ROS 234 dioxalate

ROS 234 dioxalate
(CAS: 184576-87-2)

ROS 234 dioxalate is a potent H3 antagonist (pKB at guinea-pig ileum H3-receptor = 9.46).

CAS 562-10-7 Doxylamine Succinate

Doxylamine Succinate
(CAS: 562-10-7)

Doxylamine succinate competitively inhibits histamine at H1 receptors with substantial sedative and anticholinergic effects.

CAS 87848-99-5 Acrivastine

(CAS: 87848-99-5)

Acrivastine, also known as BW825C, is an antihistamine with peripheral H1-antagonist potency equal to that of triprolidine for the treatment of allergic rhiniti...

Famotine hydrochloride
(CAS: 10500-82-0)

Famotine hydrochloride is a histamine H2 receptor antagonist. lt has no effect on the cytochrome P450 enzyme system, and does not appear to interact with other ...

CAS 64-89-1 Propiomazine Hydrochloride

Propiomazine Hydrochloride
(CAS: 64-89-1)

Propiomazine Hydrochloride is an antihistamine blocking H1 receptors. It is used to treat insomnia and to produce drowsiness. It is also used to relieve anxiety...

CAS 56897-53-1 Carcinine ditrifluoroacetate

Carcinine ditrifluoroacetate
(CAS: 56897-53-1)

The ditrifluoroacetate salt form of Carcinine, which is a highly selective histamine H3 receptor antagonist and could act as a natural antioxidant.

CAS 79516-68-0 Levocabastine

(CAS: 79516-68-0)

Levocabastine is a selective second-generation Histamine H1 receptor antagonist. It is used for Allergic conjunctivitis and Seasonal allergic rhinitis。Levocabas...

(CAS: 149440-36-8)

GS-283, an isoquinolin derivative, has been found to be histamine receptor and muscarinic receptor blocker.

CAS 34580-14-8 Ketotifen Fumarate

Ketotifen Fumarate
(CAS: 34580-14-8)

Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumar...

CAS 184025-18-1 Ciproxifan

(CAS: 184025-18-1)

Ciproxifan is a highly potent and selective histamin H3-receptor antagonist with IC50 of 9.2 nM, with low apparent affinity at other receptor subtypes.

CAS 84545-30-2 ICI 162,846

ICI 162,846
(CAS: 84545-30-2)

ICI 162,846 is a potent histamine H2 receptor antagonist.

Chemical Structure

CAS 99291-25-5 Levodropropizine

Quick Inquiry

Verification code

Featured Items